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ABSTRACT
Asmore women survive allogeneic stem cell transplantation (SCT), the development of genital human papilloma
virus (HPV)-related squamous intraepithelial lesions (SIL) warrants study. Thirty-five of 38 females followed
prospectively long-term after SCT for hematological malignancies (median: 7 years posttransplant) were adults
and had cervical cytology testing. Acute graft-versus-host-disease (aGVHD) occurred in 9 and chronic (cGVHD)
in 34 patients. Six (17%) continued receiving systemic immunosuppressive therapy (IST) for cGVHD .3 years
after SCT. Of 15 (43%) with abnormal cytology, 12 (34%) patients had HPV-related SIL (median time to SIL 51
months, range: 22-108) including high-grade SIL in 7 (20%). Patients requiring continued IST had the highest
risk (odds ratio [OR] 4.6, 95% confidence interval [CI] 1.1-16.4; P 5 .019). This high incidence of SIL in long-
term SCT survivors underscores the importance of gynecologic assessment after transplantation, especially in
those requiring IST. This may portend an increased risk of genital or other HPV-related malignancies.
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As nearly 90% of patients alive 2 years after allo-
geneic stem cell transplantation (SCT) will become
long-term survivors [1], the focus of care has shifted
from cure of the original disease to the identification
and treatment of delayed and long-term complica-
tions that may affect quality of life. Chronic
GVHD (cGVHD) has attracted most attention, but
large retrospective cohort analyses identify high
frequencies of other problems such as hypothyroid-
ism, second cancers, infertility, bone loss, and pulmo-1072nary complications [2-6]. Because systematic
prospective studies of long-term survivors after
SCT are lacking, we developed an observational pro-
tocol to follow long-term survivors of SCT. Patients
were enrolled at their third annual visit after trans-
plantation. Annual screening included evaluation for
cGVHD, major organ dysfunction, second malignan-
cies, hormonal profile, gynecologic examination, and
quality of life. Here, we present the risk of genital hu-
man papilloma virus (HPV)-related squamous intrae-
pithelial lesions (SIL) in an adult female cohort with
a 7-year median survival posttransplant.
Cervical Dysplasia following Allogeneic Stem Cell Transplantation 1073STUDY DESIGN, PATIENTS, AND METHODS
Four hundred seventeen patients with hemato-
logic disorders received SCT from an HLA identi-
cal sibling between 1993 and 2003. We conducted
a cross-sectional study of patients a minimum of 3
years posttransplantation between April 2005 and
July 2007 in an institutional review board-approved
protocol (NHLBI 05-H-0130;ClinicalTrials.gov
Identifier NCT00106925). Of the 111 patients sur-
viving 3 or more years at study initiation in 2005,
92 (83%) patients gave written informed consent,
of whom, 38 were female. Of these, 35 were adults
and 3 were children. Annual gynecologic examina-
tion was undertaken in all adult (n 5 35) female
patients over age 18 years at posttransplant fol-
low-up. Medical records from their home gynecolo-
gist were also reviewed. In this cohort, transplant
conditioning mainly consisted of total body irradia-
tion (TBI) 12-13.6 Gy and cyclophosphamide (with
or without additional fludarabine), followed by a al-
logeneic SCT (n 5 29). Nine received reduced-in-
tensity conditioning (RIC) of fludarabine 125 mg/
m2 and cyclophosphamide 60 mg/kg  2 days, fol-
lowed by a peripheral blood stem cell transplant
(PBSCT). All received cyclosporine as GVHD pro-
phylaxis.
Annual gynecologic examination included assess-
ment for vulvovaginal GVHD [7] and cervical cytology
testing. Cytology abnormalities were classified accord-
ing to the Bethesda 2001 classification system. Those
classified as atypical cells of uncertain significance
were accompanied byHPV subtyping (Digene Corpo-
ration, Gaithersburg, MD), and reported as low risk
(HPV DNA 6, 11, 42, 43, 44) and high risk (HPV
DNA 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59,
69). All women with at least low grade squamous intra-
epithelial lesions on cytology and those with vaginal
or vulvar lesions underwent biopsy of affected areas
(vulva, vagina, or cervix) to diagnose the grade of dys-
plasia. Any found to have moderate dysplasia or worse,
and some with only genital wart disease underwent
treatment. If abnormal test results were found, the
earliest occurrence posttransplant of the most severe
abnormal result was used in the analysis.
Statistical Analysis
Clinical and transplant characteristics were used to
evaluate risk factors for SIL. Age (at transplantation as
well as at time of diagnosis of cervical dysplasia) and
duration of follow-upwere included as continuous var-
iables. Other clinical variables included disease risk:
standard versus high (standard risk included patients
in first complete remission with ALL and AML, and
those with chronic phase CML) ; duration of follow-
up\10 versus $10 years; systemic immunosuppres-
sive therapy:\3 versus $3 years post-SCT; aGVHD(grade II-IV): present versus absent; cGVHD present
versus absent; genital cGVHD [7] present versus ab-
sent. In univariate analyses, chi-squared or Fisher’s
exact tests were used for categoric variables and
Mann-Whitney U-test for continuous variables. Lo-
gistic regression was used for multivariate analysis,
which included factors found to be significant in uni-
variate analyses. Statistical significance was accepted
at P\ .05. Data analysis was performed using SPSS
15 for Windows (SPSS Inc., Chicago, IL) software.
RESULTS
Female patients (n5 38) ranged from 9 to 60 years
(median 33) at time of transplantation. All were alive at
a median follow-up of 85 months (range: 45-163) post-
SCT. In the 35 adult women, grade II-IV acute
GVHD (aGVHD) occurred in 9 (27.5%) patients
and cGVHD in 34 (97%), which was extensive in 10
(26%). Six (17%) continued on immunosuppressive
treatment beyond 3 years from transplantation.
Cervical Dysplasia
Most patients had normal cervical cytology testing
prior to transplantation. One had undergone multiple
cone biopsies and a hysterectomy pretransplant and
another was noted to have genital warts within the first
90 days posttransplant. Of 35 patients with posttrans-
plant cervical cytology testing, 15 (43%) were abnor-
mal. Twelve (34%) samples with SIL all showed
biopsy-proven HPV disease; 7 (20%) had high-grade
lesions and low grade in 5 (14%). The other 3 patients
with abnormal cytology had atypical cells of undeter-
mined significance (ASCUS) negative for HPV sub-
typing. The median time to developing SIL was 51
months (range: 22-108) posttransplantation. Patients
with an abnormal cytology had a median age of 42
years (range: 19-62). Eight of 29 (28%) patients had
genital GVHD [7], there was no association between
genital GHVD and HPV-related cervical dysplasia (3
of 7 with genital GVHD had cervical dysplasia versus
5 of 21 without genital GVHD; P5 .37). Multivariate
logistic regression analysis showedHPV-related cervi-
cal dysplasia was significantly associated only with
cGVHD requiring prolonged systemic immunosup-
pressive therapy (odds ratio [OR] 4.6, 95% confidence
interval [CI] 1.1-16.4; P 5 .019): 5 of 6 versus 7 of 29
patients (Figure 1).
DISCUSSION
Our study demonstrates that genital HPV disease
is a significant late complication of allo-SCT in
women; occurring in one-third of our long-term survi-
vors. This high rate of HPV-related genital dysplasia
in patients who are cured of their underlying disease
is of concern. As anticipated, prolonged systemic
immunosuppressive treatment for cGVHD was
1074 B. N. Savani et al.associated with a higher risk of developing HPV-re-
lated SIL. This may follow a loss of protective cell
and antibody-mediated HPV immunity after SCT
leading to reactivation of latent virus. We recently
described a similar risk of hepatitis B reactivation
following the loss of protective anti-HBs antibody
posttransplantation [8].
Other immunocompromised populations are at
increased risk of HPV-related SIL and cancers.
Among solid organ transplant recipients, lower gen-
ital tract dysplasia is common [9-11]. Also, HPV was
detected in 70% to 90% of cutaneous squamous cell
cancers [12,13]. Similarly, HPV disease is common
and difficult to treat in patients with HIV [14-17].
Although this is the first analysis of risk factors for
HPV related cervical dysplasia, there are previous
reports of increased incidence of abnormal cervical
cytology and condyloma following allo-SCT [18-
20]. Our study also details for the first time the prev-
alence of high-risk versus low-risk HPV serotypes.
This is important in the light of the newly available
HPV vaccine.
Second neoplasias are a significant long-term com-
plication after allo-SCT [3,4]. In a large multicenter
European study, the actuarial risk of second malig-
nances at 15 years was 11.56 2.3% [3]. The most fre-
quent cancers occurred in skin, oral cavity, larynx,
cervix, and uterus, many of which were squamous
cell cancers. The factors associated with developing
these cancers were older age and cGVHD. Rosenberg
et al. [21] also reported a higher risk of squamous cell
cancer (SCC) in Fanconi Anemia patients after trans-
plant who had either acute or cGVHD [21]. Bhatia
et al. [4] also reported an increased risk of squamous
cell cancers, specifically oral cavity and cervical cancer,
in long-term survivors of allo-SCT. Although squa-
mous cell cancers involving these sites are associated
with HPV infection, the relation between HPV infec-
tion and second cancers is not known in SCT survivors
[12,13,22-24].
Our findings argue for regular gynecologic exami-
nation and cervical cytology testing after SCT, not
IST >3 year IST <3 year
0
10
20
30
40 Dysplasia
No Dysplasia
p=0.012
N
o
 
o
f
 
p
a
t
i
e
n
t
s
Figure 1. Duration of immunosuppressive therapy (IST) and cervi-
cal dysplasia.only to identify abnormal cytology but also to diagnose
and treat genital cGVHD. Studies are clearly needed
to determine if squamous cell cancers, as the most
common second malignancies after allo-SCT, are
HPV-related. Consideration should be given to assess-
ing pretransplant HPV antibodies to identify patients
at risk for disease reactivation. If such a strong rela-
tionship between HPV and second malignancies after
SCT exists, studies to evaluate the immunogenicity
and efficacy of quadrivalent HPV vaccine (subtypes
6, 11, 16, 18) should be considered in both male and
female patients.
Our study is limited by the fact that we did not have
a control group but our data shows that patients receiv-
ing prolonged IST have a higher risk of developing
HPV-related cervical dysplasia. This group could be
targeted for preemptive strategies including aggressive
screening and vaccinations to prevent HPV-related
SCC in allo-SCT recipients.
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